Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-04-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于2024年第一季度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the provision for asset impairment for the first quarter of 2024. It details the amounts of credit impairment losses and asset impairment losses recognized in the quarter, explaining the accounting basis and impact on the company's financial results. The document is relatively short (1176 characters) and serves as a formal disclosure of impairment provisions rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a specific financial update announcement about impairment provisions. This fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-28 Chinese
美迪西：第三届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Shanghai Medicilon Inc. It details the convening of the 21st meeting of the 3rd board, including the approval of the company's 2024 Q1 report and a share repurchase plan. The document includes voting results and references the actual Q1 report and share repurchase announcement published separately on the Shanghai Stock Exchange website. The document itself does not contain the full quarterly report or detailed financial statements but rather announces the board's resolutions and approvals. It also includes a share repurchase plan approval. Given the content, this is a Board/Management Information (MANG) filing because it announces board meeting decisions, including approval of financial reports and share repurchase plans, but does not contain the reports themselves. The document length is short (1386 characters), consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2024-04-28 Chinese
美迪西：审计委员会对立信会计师事务所（特殊普通合伙）履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the audit firm (Lixin CPA Firm) for the company's 2023 annual audit. It details the audit firm's qualifications, the procedures for appointment, the audit work performed for the 2023 fiscal year, and the committee's evaluation of the audit firm's performance. The document references the 2023 annual audit and the issuance of an unqualified audit report but does not contain the full annual report or financial statements itself. The document is 2076 characters long, which is relatively short and reads as a supervisory or audit report rather than the full Annual Report (10-K). This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report describing the audit firm's work and oversight, not the full annual report. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-23 Chinese
美迪西：董事会议事规则（2024年4月修订）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of Shanghai Medicilon Inc. It details the governance structure, composition, powers, meeting procedures, and responsibilities of the board of directors. It is a governance document outlining internal rules and procedures for the board rather than a financial report, announcement, or other regulatory filing. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, no audit opinions, or other report types. The content fits the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2024-04-23 Chinese
美迪西：立信会计师事务所（特殊普通合伙）关于公司2023年度非经营性资金占用及其他关联资金往来情况的专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" (special audit report) concerning non-operating fund occupation and other related party fund transactions for Shanghai Medicilon Biopharmaceutical Co., Ltd. for the year 2023. It is issued by an accounting firm (立信会计师事务所) and contains detailed tables of fund balances and transactions. The content is a standalone audit report focusing on specific financial matters related to non-operating funds and related party transactions, rather than a full annual report or interim report. It does not appear to be a general regulatory filing, announcement, or presentation. Therefore, the document fits the category of an Audit Report / Information (AR). The document length is 2297 characters, which is consistent with a detailed audit report but not a brief announcement or certification. FY 2023
2024-04-23 Chinese
美迪西：2024年度“提质增效重回报”行动方案
Board/Management Information Classification · 75% confidence The document is titled as a 2024 annual action plan by Shanghai Medicilon Biopharmaceutical Co., Ltd. It outlines strategic initiatives for quality improvement, efficiency, governance, investor communication, and shareholder return mechanisms for the year 2024. The content is a detailed operational and strategic plan rather than a financial report or earnings release. It includes no financial statements or quantitative financial results, nor does it announce voting results or management changes. The document length is 4125 characters, which is relatively short but contains substantive content about company strategy and governance improvements. It is not a report publication announcement since it does not mention an attached report or provide a link. The document focuses on management plans and governance enhancements, which aligns best with Board/Management Information (MANG) as it relates to company governance and management strategic plans. Therefore, the most appropriate classification is MANG with moderate confidence due to the strategic nature of the content and absence of financial data or formal report structure.
2024-04-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.